Definium reports another Phase 3 win for LSD-based anxiety drug DT120 on September 14, 2026 Definium Therapeutics DT120 Generalized Anxiety Disorder HAM-A Lysergic Acid Diethylamide NDA Panorama trial Phase 3 placebo-adjusted efficacy psychedelic biotech +